Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Commentary on: Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalisation or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2017;318:713–720.
Natriuretic peptides (NPs), a collective term for B-type natriuretic peptide (BNP) and N(or amino)-terminal pro-B-type natriuretic peptide (NT-proBNP), are released by the myocardium in response to pressure or fluid overload. In patients with heart failure (HF) the NP levels are raised. NP testing is currently used in diagnosis and prognosis, but its role in guiding HF treatment remains uncertain. The guidelines do not currently recommend NP-guided treatment. Previous clinical trials and meta-analyses have researched NP-guided treatment with mixed results.1–6 Felker et al, in the Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) study, aimed to …
Contributors JM and CB critically assessed the study, and drafted and agreed on the final manuscript.
Funding This article presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Reference Number RP-PG-1210-12003). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.